Get startedLog in
    Picture of Akero Therapeutics logo

    AKRO — Akero Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Akero Therapeutics’ Phase 2B Symmetry Cohort D Study Meets Safety, Tolerability Endpoints

    Picture of Akero Therapeutics logoAkero Therapeutics
    05/06/2023 12:46
    June 5 (Reuters) - Akero Therapeutics Inc  AKRO.O :
    * AKERO THERAPEUTICS’ PHASE 2B SYMMETRY COHORT D STUDY MET
SAFETY
& TOLERABILITY ENDPOINTS AND SHOWED ADDING EFX TO GLP-1 THERAPY
SIGNIFICANTLY IMPROVED NON-INVASIVE MARKERS OF NASH-RELATED
DISEASE
    * AKERO THERAPEUTICS INC - EFX WAS REPORTED TO BE GENERALLY
WELL
TOLERATED IN COHORT D WITH COMPARABLE RESULTS FOR EFX (N=21) AND
PLACEBO (N=10) GROUPS
    * AKERO THERAPEUTICS INC - EFX'S OVERALL TOLERABILITY
PROFILE WAS
SIMILAR TO THAT OBSERVED IN AKERO'S BALANCED AND HARMONY STUDIES

Source text for Eikon:  ID:nGNX9kxmLv 
Further company coverage:  AKRO.O 

 ((Reuters.Briefs@thomsonreuters.com))

    Recent news on Akero Therapeutics

    See all news